Abstract
In a pivotal trial, a 5-day course of oral ritonavir-boosted nirmatrelvir, given early during symptomatic infection, decreased hospitalization and death by 89.1% and reduced nasal viral load by 0.87 log relative to placebo in high-risk individuals. Yet, ritonavir-boosted nirmatrelvir failed as post-exposure prophylaxis in a follow-up trial, and frequent viral rebound has been observed in the community. We developed a mathematical model capturing viral-immune dynamics and nirmatrelvir pharmacokinetics that recapitulated viral loads from this and another clinical trial. Our results suggest that nirmatrelvir’s in vivo potency is significantly lower than in vitro assays predict. A maximally potent agent would reduce the viral load by approximately 3.5 logs relative to placebo at 5 days. The model identifies that earlier initiation and shorter treatment duration are key predictors of post-treatment rebound. Extension of early symptomatic treatment to 10 days and post-exposure prophylaxis to 15 days, rather than increasing dose or dosing frequency, is predicted to significantly lower the incidence of viral rebound.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Institutes of Health (NIH) grants R01AI169427, R01AI121129, and R01AI177512
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data analyzed in this work was previously published by Hay et al. and Schilling et al. and is available on github at https://github.com/gradlab/SC2-kinetics-immune-history and https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We updated the viral dynamics model and fit our model to data from a second published Paxlovid trial (PLATCOV study). We performed a sensitivity analysis to show that variability in the drug's PK does not impact the predictions of this paper. Further, we identify that varying the Hill coefficient for the PD component of the model does not have any meaningful impact on model predictions.
Data Availability
All code, and materials used in the analysis is available on github at https://github.com/sEsmaeili/Covid_Rebound The data analyzed in this work was previously published by Hay et al. and Schilling et al. and is available on github at https://github.com/gradlab/SC2-kinetics-immune-history and https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0
https://github.com/gradlab/SC2-kinetics-immune-history
https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0